Angiotensin II-induced cardiomyocyte hypertrophy in vitro is TAK1-dependent and Smad2/3-independent

Hypertension Research

Volumn 35, Issue 4, 2012, Pages 393-398

  Watkins, Sarah J ^a   Borthwick, Gillian M ^a   Oakenfull, Rachael ^a   Robson, Andrew ^a   Arthur, Helen M ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

angiotensin; cardiomyocyte; hypertrophy; smad; tak1

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ANGIOTENSIN II; BRAIN NATRIURETIC PEPTIDE; SMAD2 PROTEIN; SMAD3 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL SIZE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; IN VIVO STUDY; NEWBORN; NONHUMAN; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; STRESS FIBER;

ANGIOTENSIN II; ANIMALS; ANIMALS, NEWBORN; CARDIOMEGALY; CELLS, CULTURED; MAP KINASE KINASE KINASES; MYOCYTES, CARDIAC; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84859595474     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.196     Document Type: Article

References (26)

1. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004; 63: 423-432. (Pubitemid 38970186)
2. Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 1993; 73: 413-423. (Pubitemid 23238726)
3. Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-beta signaling in cardiac remodeling. J Mol Cell Cardiol 2011; 51: 600-606
4. Bujak M, Frangogiannis NG. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 2007; 74: 184-195. (Pubitemid 46517504)
5. Rosenkranz S, Flesch M, Amann K, Haeuseler C, Kilter H, Seeland U, Schluter KD, Bohm M. Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta. American Journal of Physiology 2002; 283: H1253-H1262.
6. Schultz Jel J, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL, Kimball TR, Doetschman T. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Investigat 2002; 109: 787-796. (Pubitemid 34263155)
7. Schmierer B, Hill CS. TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 2007; 8: 970-982. (Pubitemid 350174642)
8. Shim JH, Xiao C, Paschal AE, Bailey ST, Rao P, Hayden MS, Lee KY, Bussey C, Steckel M, Tanaka N, Yamada G, Akira S, Matsumoto K, Ghosh S. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev 2005; 19: 2668-2681. (Pubitemid 41627934)
9. Zhang D, Gaussin V, Taffet GE, Belaguli NS, Yamada M, Schwartz RJ, Michael LH, Overbeek PA, Schneider MD. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med 2000; 6: 556-563. (Pubitemid 30305906)
10. Matsumoto-Ida M, Takimoto Y, Aoyama T, Akao M, Takeda T, Kita T. Activation of TGFbeta1- TAK1-p38 MAPK pathway in spared cardiomyocytes is involved in left ventricular remodeling after myocardial infarction in rats. American Journal of Physiology 2006; 290: H709-H715.
11. Watkins SJ, Jonker L, Arthur HM. A direct interaction between TGFbeta activated kinase 1 and the TGFbeta type II receptor: implications for TGFbeta signalling and cardiac hypertrophy. Cardiovasc Res 2006; 69: 432-439. (Pubitemid 43098799)
12. Nakagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I, Nishino K, Yoshimasa T, Nakao K. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an 'emergency' cardiac hormone against ventricular overload. J Clin Investigat 1995; 96: 1280-1287.
13. Watkins SJ, Borthwick GM, Arthur HM. The H9C2 cell line and primary neonatal cardiomyocyte cells show similar hypertrophic responses in vitro. In Vitro Cell Dev Biol Anim 2011; 47: 125-131.
14. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002; 62: 65-74. (Pubitemid 34680517)
15. Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C, Karlsson S, ten Dijke P. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell 2003; 12: 817-828. (Pubitemid 37352776)
16. Frank D, Kuhn C, van Eickels M, Gehring D, Hanselmann C, Lippl S, Will R, Katus HA, Frey N. Calsarcin-1 protects against angiotensin-II induced cardiac hypertrophy. Circulation 2007; 116: 2587-2596. (Pubitemid 350179222)
17. Sheng L, Ye P, Liu YX, Han CG, Zhang ZY. Peroxisome proliferator- activated receptor beta/delta activation improves angiotensin II-induced cardiac hypertrophy in vitro. Clin Exp Hypertens 2008; 30: 109-119. (Pubitemid 351302225)
18. Wang Y, Su B, Sah VP, Brown JH, Han J, Chien KR. Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells. J Biol Chem 1998; 273: 5423-5426. (Pubitemid 28124000)
19. Lim JY, Park SJ, Hwang HY, Park EJ, Nam JH, Kim J, Park SI. TGF-beta1 induces cardiac hypertrophic responses via PKC-dependent ATF-2 activation. J Mol Cell Cardiol 2005; 39: 627-636. (Pubitemid 41331051)
20. Doyon P, Servant MJ. Tumor necrosis factor receptor-associated factor-6 and ribosomal S6 kinase intracellular pathways link the angiotensin II AT1 receptor to the phosphorylation and activation of the IkappaB kinase complex in vascular smooth muscle cells. J Biol Chem 2010; 285: 30708-30718.
21. Yang F, Chung AC, Huang XR, Lan HY. Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways: the role of Smad3. Hypertension 2009; 54: 877-884.
22. Koitabashi N, Danner T, Zaiman AL, Pinto YM, Rowell J, Mankowski J, Zhang D, Nakamura T, Takimoto E, Kass DA. Pivotal role of cardiomyocyte TGF-beta signaling in the murine pathological response to sustained pressure overload. J Clin Investigat 2011; 121: 2301-2312.
23. Teekakirikul P, Eminaga S, Toka O, Alcalai R, Wang L, Wakimoto H, Nayor M, Konno T, Gorham JM, Wolf CM, Kim JB, Schmitt JP, Molkentin JD, Norris RA, Tager AM, Hoffman SR, Markwald RR, Seidman CE, Seidman JG. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-beta. J Clin Investigat 2010; 120: 3520-3529.
24. Wang J, Xu N, Feng X, Hou N, Zhang J, Cheng X, Chen Y, Zhang Y, Yang X. Targeted disruption of Smad4 in cardiomyocytes results in cardiac hypertrophy and heart failure. Circ Res 2005; 97: 821-828. (Pubitemid 41447133)
25. Tan SM, Zhang Y, Connelly KA, Gilbert RE, Kelly DJ. Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction. Am J Physiol Cell Physiol 2010; 298: H1415-H1425.
26. Courties G, Seiffart V, Presumey J, Escriou V, Scherman D, Zwerina J, Ruiz G, Zietara N, Jablonska J, Weiss S, Hoffmann A, Jorgensen C, Apparailly F, Gross G. In vivo RNAimediated silencing of TAK1 decreases inflammatory Th1 and Th17 cells through targeting of myeloid cells. Blood 2010; 116: 3505-3516.